BNCT past and present

The advancement of boron neutron capture therapy has been a collaborative, international effort that has spanned nearly a century


American astrophysicist Gordon Locher hypothesizes that the interaction between neutrons released from radium and captured by beryllium could be used to kill tumor cells


Neurosurgeon Dr. William Herbert Sweet of Massachusetts General Hospital and physicist Gordon Lee Brownell of MIT conduct the first clinical trial of boron neutron capture therapy for patients with brain tumors


Hiroshi Hatanaka begins clinical BNCT program in Japan following his work in the U.S.


Interest is renewed in BNCT with clinical programs initiated in the U.S., Europe and Japan for “second-generation” boron compounds.

In 1999, Helsinki University Hospital in Helsinki, Finland, began treating patients with neutrons obtained from a nuclear reactor source (FiR 1) and using l-boronophenylalanine-fructose (l-BPA-F) as the boron delivery agent.


Phase 1 clinical study in Japan is initiated in the first trial using neutron accelerator for neutron delivery


Results of Phase 2 trial in Japan show an overall response rate of ~70% for patients with recurrent squamous cell carcinoma or advanced non-squamous cell carcinoma.

Steboronine® is approved by the PMDA in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. This marked the first drug approval for BNCT.


Aviko is founded by Deerfield Management to advance BNCT and build a treatment ecosystem in U.S. along with partners.

Advancing BNCT

Learn more about how BNCT precisely targets tumors

BNCT minimizes damage to healthy cells as boron medicines remain inert until they are activated by a neutron beam at the site of the tumor